N/A
N=29
Neuromuscular Electrical Stimulation and Mobility in Multiple Sclerosis
Multiple Sclerosis
Bottom Line
View on ClinicalTrials.gov: NCT02152085 ↗Enrolled (actual)
29
Serious AEs
0.0%
Results posted
May 2021
Primary outcome: Primary: Walking Endurance — 42; 25 meters
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Narrow pulse (Device); Wide pulse (Device)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Colorado, Boulder
- Primary completion
- Dec 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Walking Endurance |
42; 25 | — |
| PRIMARY Modified Fatigue Impact Scale |
34; 23 | — |
| SECONDARY Maximal Walking Speed |
-1.92; 0.12 | — |
Summary
The purpose of this study is to investigate the capacity of a 6-week treatment with neuromuscular electrical stimulation to improve walking in individuals whose mobility has been compromised by multiple sclerosis.
Eligibility Criteria
Inclusion Criteria
- Able to read, understand, and speak English to ensure safe participation in the project
- Difficulties with walking
- On stable doses of Ampyra, provigil, or other symptomatic-treating medications
- No systemic steroids within the last 30 days
- Not currently exercising more than 2x/wk
- Able to arrange own transportation to and from the laboratories
- Provide informed consent, including willingness to be randomly assigned to one of the two groups
Exclusion Criteria
- Documented MS-related relapse in the last 3 months
- Medical diagnosis or condition that is considered to be an absolute or relative contraindication to participating in exercise training, such as major renal, pulmonary, hepatic, cardiac, gastrointestinal, HIV, cancer (other than treated basal cell cancer), other neurological disorders, or pregnancy
- Poorly controlled diabetes mellitus or hypertension
- History of seizure disorders
- Alcohol dependence or abuse (≥2 drinks/day), or present history (last 6 months) of drug abuse
- Inability to attend exercise sessions 3 days per week for 6 weeks
Data sourced from ClinicalTrials.gov (NCT02152085). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.